Culture of microbial organisms was for more than a century the diagnostic centerpiece of etiological diagnosis of infections. Particularly in immunocompromised hosts other methods for ascertaining microbial complications have supplemented culture systems. The surge of interest in the human microbiome, which is in its infancy, holds the promise of important insights, and the PM cooperation is placed squarely in this field.
To follow and add to the development of new diagnostic tools, that more closely reflect the need for therapeutic intervention in the immunocompromised host than traditional methods.
To develop risk based algorithms to decide whether to expose immunodeficient patients to antimicrobial therapy, or to spare them the side effects of this as regards their intact, undisturbed microbiome.